Item 16. FORM 10-K SUMMARY
5K characters. Original on sec.gov · Markdown
Item 16. FORM 10-K SUMMARY
Not applicable.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CENCORA, INC. | |||||||||||
| Date: November 25, 2025 | By: | /s/ ROBERT P. MAUCH | |||||||||
| Robert P. Mauch | |||||||||||
| President, Chief Executive Officer, and Director |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below as of November 25, 2025 by the following persons on behalf of the Registrant and in the capacities indicated.
| Signature | Title | |||||||
| /s/ ROBERT P. MAUCH | President, Chief Executive Officer, and Director | |||||||
| Robert P. Mauch | (Principal Executive Officer) | |||||||
| /s/ JAMES F. CLEARY | Executive Vice President and Chief Financial Officer | |||||||
| James F. Cleary | (Principal Financial Officer) | |||||||
| /s/ LAZARUS KRIKORIAN | Senior Vice President and Chief Accounting Officer | |||||||
| Lazarus Krikorian | (Principal Accounting Officer) | |||||||
| /s/ WERNER BAUMANN | Director | |||||||
| Werner Baumann | ||||||||
| /s/ FRANK K. CLYBURN | Director | |||||||
| Frank K. Clyburn | ||||||||
| /s/ D. MARK DURCAN | Chair and Director | |||||||
| D. Mark Durcan | ||||||||
| /s/ LON R. GREENBERG | Director | |||||||
| Lon R. Greenberg | ||||||||
| /s/ LORENCE H. KIM, M.D. | Director | |||||||
| Lorence H. Kim, M.D. | ||||||||
| /s/ REDONDA G. MILLER, M.D. | Director | |||||||
| Redonda G. Miller, M.D. | ||||||||
| /s/ DENNIS M. NALLY | Director | |||||||
| Dennis M. Nally |
| Signature | Title | |||||||
| /s/ LORI J. RYERKERK | Director | |||||||
| Lori J. Ryerkerk | ||||||||
| /s/ LAUREN M. TYLER | Director | |||||||
| Lauren M. Tyler |
CENCORA, INC. AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
| (In thousands) | Balance at Beginning of Period | Charged to Costs and Expenses (1) | Deductions (2) | Balance at End of Period | ||||||||||||||||||||||
| Year Ended September 30, 2025 | ||||||||||||||||||||||||||
| Allowances for returns and credit losses | $ | 1,308,018 | $ | 6,298,400 | $ | (5,810,246) | $ | 1,796,172 | ||||||||||||||||||
| Year Ended September 30, 2024 | ||||||||||||||||||||||||||
| Allowances for returns and credit losses | $ | 1,433,396 | $ | 4,488,174 | $ | (4,613,552) | $ | 1,308,018 | ||||||||||||||||||
| Year Ended September 30, 2023 | ||||||||||||||||||||||||||
| Allowances for returns and credit losses | $ | 1,626,729 | $ | 4,846,067 | $ | (5,039,400) | $ | 1,433,396 |
(1)Represents the provision for returns and credit losses.
(2)Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.
Previous: Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES